QURE - uniQure N.V. Short-Term Debt to Capital

The price action visualization on GURU.Markets for uniQure N.V. (QURE) demonstrates the development of a business scaling gene therapy through international licensing agreements, with the indicator standing at 0.15. uniQure N.V. (QURE) maintains market priority due to patents for a unique single-injection hemophilia treatment method. Simultaneously, the company is developing breakthrough drugs for Huntington's disease using AAV vectors to combat rare genetic defects.

For uniQure N.V. (QURE), the dynamics of short-term loans relative to equity serve as an indicator of operational resilience when financing costly R&D. The ratio of liabilities maturing within one year to capital determines the company's dependence on external liquid borrowing, which is critical for a biotech firm with high pricing power and unique patent revenues from gene therapy.